Tempus AI (NASDAQ:TEM) Shares Gap Down to $39.04

Tempus AI, Inc. (NASDAQ:TEM)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $39.04, but opened at $32.82. Tempus AI shares last traded at $36.15, with a volume of 215,767 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Stifel Nicolaus started coverage on shares of Tempus AI in a report on Tuesday, July 9th. They set a “buy” rating and a $45.00 price objective on the stock. TD Cowen began coverage on shares of Tempus AI in a report on Tuesday, July 9th. They set a “buy” rating and a $50.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and set a $47.00 price target on shares of Tempus AI in a research report on Wednesday. Bank of America started coverage on shares of Tempus AI in a research note on Tuesday, July 9th. They issued a “buy” rating and a $41.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their target price on Tempus AI from $42.00 to $47.00 and gave the stock an “overweight” rating in a research note on Wednesday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $46.25.

Tempus AI Trading Down 4.5 %

Institutional Trading of Tempus AI

A number of institutional investors have recently added to or reduced their stakes in TEM. Alphabet Inc. bought a new stake in Tempus AI during the second quarter valued at approximately $54,289,000. Northwestern University purchased a new position in Tempus AI in the second quarter worth $491,000. ARK Investment Management LLC bought a new position in Tempus AI in the second quarter valued at $18,294,000. Finally, EFG Asset Management North America Corp. bought a new stake in Tempus AI during the second quarter worth about $1,333,000.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.